首页 | 本学科首页   官方微博 | 高级检索  
检索        

吡格列酮二甲双胍片联合诺和锐30治疗Ⅱ型糖尿病的临床分析
引用本文:刘霞.吡格列酮二甲双胍片联合诺和锐30治疗Ⅱ型糖尿病的临床分析[J].西部医学,2014,26(10):1306-1309.
作者姓名:刘霞
作者单位:榆林市中医医院·北方医院内分泌科,陕西榆林719000
摘    要:目的 探讨吡格列酮二甲双胍片(卡双平)联合诺和锐30对改善Ⅱ型糖尿病(T2DM)血糖、血脂、糖化血红蛋白、C-肽、体重指数、胰岛素用量及低血糖反应的临床效果.方法 将就诊的300例T2DM患者随机分为对照组150例及观察组150例,对照组患者单纯给予胰岛素治疗,观察组在对照组用药的基础上给予吡格列酮二甲双胍片治疗,观察两组患者治疗后6个月血糖、血脂、糖化血红蛋白、C-肽、体重指数、胰岛素用量及低血糖等指标的变化.结果 观察组治疗后FPG、2hPG、HbAlc、TC、TG、LDL-C显著低于对照组,而HDL-C高于对照组(P<0.05).观察组治疗后胰岛素用量小于对照组,空腹C-肽(C-P)、餐后2h C-P则高于对照组(P<0.05).观察组餐后低血糖发生率为1.33%,对照组为10.67% (P<0.05).治疗前体重指数无统计学差异,治疗后观察组与对照组体重指数有显著差异(P<0.05).结论 对T2MD患者应用吡格列酮二甲双胍片联合诺和锐30治疗能有效改善患者血糖、血脂、糖化血红蛋白,并可改善胰岛功能,减少胰岛素的用量,同时减轻体重,减少低血糖反应发生.

关 键 词:Ⅱ型糖尿病  吡格列酮二甲双胍片  诺和锐30

The clinical analysis of Pioglitazone metformin tablets and Aspart 30 in patients with T2MD
LIU Xia.The clinical analysis of Pioglitazone metformin tablets and Aspart 30 in patients with T2MD[J].Medical Journal of West China,2014,26(10):1306-1309.
Authors:LIU Xia
Institution:LIU Xia (Department of Endocrinology, Traditional Chinese Medicine Hospital of Yulin , North Hospital, Yulin 719000, Shanxi)
Abstract:Objective To investigate the effect of Pioglitazone metformin tablets and Aspart 30 ton glucose,lipids,glycated hemoglobin,C-peptide,BMI,insulin dose and hypoglycemia in Type Ⅱ diabetes.Methods 300 patients with T2MD were randomly divided into control group (n=150)and observation group(n=150).The control group was treated with Aspart 30 and observation group with Pioglitazone metformin tablets and Aspart 30.The levels of blood lipids,insulin function were analyzed.Results The levels of FPG,2hPG,HbAc,TC,TG and LDL-C of observation group were significantly lower than that of the control group and the levels of HDL-C of observation group was higher than that of control group (P〈0.05).The levels of HoMA-IR of observation group was lower than that of the control group,while the levels of B cell function index,fasting C-peptide (C-P),postprandial 2h C-P (2h C-P) of observation group were higher (P〈0.05).The rate of observation group of postprandial hypoglycemia incidence was1.33% and control group the incidence of hypoglycemia was 10.67% (P〈0.05).Before treatment,The levels of observation group of body mass index,blood glucose of two groups were not statistically significant(P〉0.05).The levels of mass index,blood glucose,body mass index of control group were higher than that of the observation group(P〈0.05).Conclusion Pioglitazone metformin tablets and Aspart 30 can improve the level of glucose and lipid islet function with T2MD,while the Pioglitazone metformin tablets can be lowered and raised Visfatin levels of ghrelin levels in T2MD sugar control mechanism of action.
Keywords:Type 2 diabetes  Pioglitazone metformin tablets  Aspart 30
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号